In his weekly clinical update, Dr. Griffin discusses the outcomes of SARS-CoV-2, influenza and respiratory syncytial virus infection in pediatric communities under the age of 18 years, the treatment of infants with the human monoclonal anti-respiratory syncytial virus antibody to prevent hospitalizations, most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US, how the SARS-CoV-2/COVID-19 pandemic affected school attendance and child healthcare, how exposure length influenced transmission of SARS-CoV-2, how the durability of the anti-SARS-CoV-2 antibody response to protect against virus re-infection, if administration of oral antiviral therapy affected viral rebound in either the unvaccinated or vaccinated populations, as well as a reminder of the ineffectiveness of antibiotics for treating COVID-19 and the effect of vaccination on post-COVID conditions in children between 5-17 years old. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Pediatric outcomes SARS-CoV-2, flu, RSV (JAMA Peds.) SARS-CoV-2 vs Flu (Wired) Anti-RSV antibody treatment for infants (NEJM) Respiratory disease surveillance (CDC) RSV surveillance (CDC) RSV national trend (CDC) Influenza/flu surveillance (CDC) COVID-19 hospital admissions (CDC) COVID-19 national trend (CDC) COVID-19 wastewater testing (biobot) COVID-19 school attendance (JPEIDS) COVID-19 pandemic effects children health care (JPEIDS) Digitally measuring transmission (Nat) Antibody titers and re-infection (CMI) Oral antiviral and SARS-CoV-2 rebound (MMWR) Rebound after antiviral controlled trial (MMWR) Vaccination and antiviral therapy (OFID) Antivirals and hospitalization (JMV) Antivirals molnupiravir (JMV) Convalescent plasma and the immunocompromised guidelines (IDSOciety) Steroid and the cytokine storm (OFID) Anticoagulation guidelines (hematology.org) Unnecessary antibiotics (NEJM) Vaccination and long COVID (OFID) RSV vaccination (MMWR) Antivirals and chronic kidney disease (CID) Early administraton of molnupiravir versus ritonavir-boosted nirmatrelvir (Lancet) Contribute to our MicrobeTV fundraiser at PWB Letters read on TWiV 1074 Dr. Griffin’s COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv
In his weekly clinical update, Dr. Griffin discusses the outcomes of SARS-CoV-2, influenza and respiratory syncytial virus infection in pediatric communities under the age of 18 years, the treatment of infants with the human monoclonal anti-respiratory syncytial virus antibody to prevent hospitalizations, most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US, how the SARS-CoV-2/COVID-19 pandemic affected school attendance and child healthcare, how exposure length influenced transmission of SARS-CoV-2, how the durability of the anti-SARS-CoV-2 antibody response to protect against virus re-infection, if administration of oral antiviral therapy affected viral rebound in either the unvaccinated or vaccinated populations, as well as a reminder of the ineffectiveness of antibiotics for treating COVID-19 and the effect of vaccination on post-COVID conditions in children between 5-17 years old.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episodeIntro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv